BridgeBio Pharma (NASDAQ:BBIO)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $31.44 and last traded at $30.74, with a volume of 4266 shares trading hands. The stock had previously closed at $27.60.

In other news, major shareholder Genetic Disorder L.P. Kkr acquired 2,647,100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was bought at an average price of $17.00 per share, with a total value of $45,000,700.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Brian C. Stephenson acquired 55,500 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was purchased at an average cost of $17.00 per share, with a total value of $943,500.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 7,408,500 shares of company stock valued at $125,944,500.

BridgeBio Pharma Company Profile (NASDAQ:BBIO)

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Recommended Story: What moving averages are used to define a golden cross?

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.